Methylenetetrahydrofolate Reductase Gene Polymorphism and Clucocorticoid Intake in Children with ALL and Aseptic Osteonecrosis

Klinische Padiatrie

Volumn 215, Issue 6, 2003, Pages 327-331

  Bernbeck, B ^a,b   Mauz Korholz C ^a   Zotz, R B ^a   Gobel U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

ALL; Aseptic osteonecrosis; Bone marrow edema; Glucocorticoids; MTHFR polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); GLUCOCORTICOID; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ARTICLE; ASEPTIC NECROSIS; BODY WEIGHT; BONE MARROW DISEASE; CHILD; CONTROLLED STUDY; DIETARY INTAKE; DISEASE PREDISPOSITION; DOSE RESPONSE; EDEMA; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADOLESCENT; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BONE MARROW DISEASES; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; EDEMA; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OSTEONECROSIS; POLYMORPHISM, GENETIC; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0346308307     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-45496     Document Type: Article

References (28)

1. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzachi JM, Costa FF. The mutation Ala677→Val in the methylene tetrahydorfolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-812
2. Barr RD, Halton J, Willan A, Cockshott WP, Gill G, Atkinson S. Impact of age and cranial irradiation on radiographic skeletal pathology in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1998; 30: 347-350
3. Bernbeck B, Krauth KA, Scherer A, Engelbrecht V. Göbel U. Aseptic osteonecrosis in a child with nephroblastoma healed by hyperbaric oxygen therapy. Med Pediatr Oncol 2002; 39: 47-48
4. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057
5. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA. Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
6. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239
7. Heijer M, Keijzer M. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med 2001; 39: 710-713
8. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. In vitro drug resistance as independent prognostic factor in the study COALL-05-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr 1999; 211: 233-238
9. Jones JP Jr. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop 1993; 292: 294-308
10. Kechli A, Wiliams J, Pui CH, Park V, Tonkel S, Deitcher SR. Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy. J Pediatr 1999; 134: 310-314
11. Kirschke R, Nurnberger W, Eckhof-Donovan S, Nürnberger I, Göbel U. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol. Klin Padiatr 1998; 210: 285-290
12. Koch HG, Nabel P, Junker R, Auberger K, Schobess R, Hornberger A, Linnebank M, Nowak-Göttl U. The 667T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr 1999; 158(Suppl3) (Suppl 3): 113-116
13. Körholz D, Bruder MD, Engelbrecht V, Rüther W, Göbel U. Aseptic osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1998; 15: 307-315
14. Mattano LA, Sather HN, Trigg ME, Nachmann JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the children's cancer group. J Clin Oncol 2000; 18: 3262-3272
15. Mauz-Körholz C, Nürnberger W, Irsfeld H, Körholz D, Göbel U. Low rate of severe venous thromboses in children with ALL treatment according to CoALL-5-92 and -97 protocol. Klin Pädiatr 1999; 211: 215-217
16. Mauz-Körholz C, Junker R, Göbel U, Nowak-Göttl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (CoALL-92 and 97 protocols). Thromb Haemos 2000; 83: 840-843
17. Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595-1599
18. Ojala AE, Lanning FP, Paakko E, Lanning BM. Osteonecrosis in children treated for acute lymphoblastic leukemia: a magnetic resonance imaging study after treatment. Med Pediatr Oncol 1997; 29: 260-265
19. Ojala AE, Paakko E, Lanning FP, Lanning M. Osteonecrosis during the treatment of childhood acute lymphoblastic leukemia: a prospective MRI study. Med Pediatr Oncol 1999; 32: 11-17
20. Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993; 52: 582-585
21. Raab P, Kühl J, Krauspe R. Multifokale Osteonekrosen bei Kindern und Jugendlichen nach Polychemotherapie. Z Orthop 1997; 135: 444-450
22. Schnyder G, Roffi M, Pin M, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-1600
23. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11: 13-16
24. Semeraro N, Montemurro P, Giordano P, Schettini F, Santoro N, de Mattia D, Giordano D, Conese M, Colucci M. Unbalanced coagulationfibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost 1990; 64: 38-40
25. Stehouwer CDA, Jakobs C. Abnormalities for vascular function in hyperhomocysteineaemia: relationship to atherothrombotic disease. Eur J Pediatr 1998; 157 (Suppl 2): S107-S111
26. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103: 294-299
27. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201
28. Wang GJ, Sweet DE, Reger SI, Thompson RC. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg 1977; 59: 729-735